Everybaby Limited

What Everybaby Limited does

Everybaby Limited is an Ireland-based medical device company developing a handheld Electrical Impedance Spectroscopy (EIS) diagnostic for preterm birth risk prediction in pregnant women. The device operates by measuring the electrical impedance of cervical tissue to predict spontaneous preterm delivery, with clinical study results (449 participants) demonstrating AUCs of 0.80–0.86 across gestational windows — a 21% accuracy improvement over transvaginal ultrasound and fetal fibronectin in high-risk cohorts. The core EIS technology is licensed from Prof. Dilly Anumba at the University of Sheffield, supported by peer-reviewed publications in Ultrasound in Obstetrics & Gynecology and Biomedical Engineering Online.

The company is pre-commercial and not yet generating revenue. Its go-to-market is enterprise field sales targeting hospitals, maternal-fetal medicine units, and obstetrics clinics, with anticipated hardware sales as the primary revenue stream. A commercial clinical trial collaboration with PureHealth (UAE) was announced in 2025 as the path toward first market entry. The company has no disclosed funding rounds, operates with 1–10 employees from its Cork headquarters, and has secured recognition across three regions (Abu Dhabi 2023, Hangzhou 2024, Hong Kong 2025) to support international expansion. The leadership team comprises CEO Dabriel Choi (former life-sciences VC fund manager), COO Sunny Gong, and CTO Dr. Gordon Scarth (25+ years medical device commercialization), supported by an advisory board including leading maternal-fetal medicine academics from the University of Sheffield, University of Sydney, Medtronic ANZ, and Ewha Womans University. Dr. Yongjin Choi's ML-based predictive modeling work, using large-scale public records, represents an emerging AI augmentation layer above the EIS hardware foundation.

Name

Everybaby Limited

Legal name

EveryBaby Limited

Website

https://every-baby.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Everybaby Limited is an Ireland-based pre-commercial medical device company developing a handheld Electrical Impedance Spectroscopy device for preterm birth risk prediction, targeting hospitals and maternal-fetal medicine providers with claims of 21% greater accuracy than existing ultrasound and fibronectin methods.

Ownership category

akta.pro rank

Product category

Maternal-Fetal Diagnostic Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ)

akta.pro secondary industry

Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI)

Keywords

• Preterm birth diagnostics
• Maternal health devices
• Electrical impedance spectroscopy
• Prenatal screening tools
• Medical device development

Headquarters

HQ city

Cork

HQ country

Ireland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Medical Device Sales: Pre-commercial stage company developing a handheld diagnostic device for preterm birth detection. Revenue model expected to be through medical device sales to healthcare providers and hospitals.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

EveryBaby develops a handheld diagnostic device powered by Electrical Impedance Spectroscopy (EIS) technology that measures cervical electrical impedance to predict spontaneous preterm birth. The device delivers 21% greater diagnostic accuracy than existing ultrasound and fibronectin-based methods, with AUC of 0.80 for high-risk groups and 0.76 for all women. It is currently pre-commercial and preparing for a commercial clinical trial in collaboration with PureHealth.

Product overview

EveryBaby offers a single unified product: the EveryBaby handheld diagnostic device. This device uses Electrical Impedance Spectroscopy (EIS) technology for preterm birth diagnostics. It delivers 21% greater diagnostic accuracy than existing methods, with AUC scores ranging from 0.76 to 0.86 depending on gestational age group and prediction window. The device is designed for use by healthcare providers worldwide to enable timely clinical interventions.

Differentiator

Problem solved

Functional benefit

Products and services

• EveryBaby Handheld Diagnostic Device A handheld diagnostic device powered by Electrical Impedance Spectroscopy (EIS) technology that measures cervical electrical impedance to predict spontaneous preterm birth. It delivers 21% greater diagnostic accuracy than existing ultrasound and fibronectin-based methods, with AUC 0.80 for high-risk groups (26-28 weeks) and AUC 0.76 for all women (20-22 weeks). It is designed for use by healthcare providers worldwide to enable timely clinical interventions.

Quantifiable outcome

• 21% greater diagnostic accuracy than existing methods
• +3 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Partnerships

One partnership is on record.

• PureHealthcoreStrategic or Co-development Partner · 1 January 2025Preparing for next commercial clinical trial in collaboration with PureHealth. This partnership represents a key step towards commercialization of EveryBaby's EIS diagnostic technology for preterm birth detection.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• CooperSurgical: Established women's-health and fertility diagnostics company with hospital-channel distribution overlapping EveryBaby's target customer base of OB/GYNs and maternal-fetal medicine units.
• Philips: Broad incumbent in maternal-fetal medicine ultrasound and women's-health diagnostics; competes for the same hospital budget and clinical workflow that EveryBaby targets.
• Hologic: Major women's-health diagnostics incumbent offering the Fetal Fibronectin test that EveryBaby's clinical study explicitly benchmarks against (AUC 0.66). Hologic has established OB/GYN distribution, reimbursement, and clinical workflow integration that EveryBaby must displace.
• GE HealthCare: Larger incumbent whose ultrasound systems are the standard transvaginal cervical-length measurement modality used today in preterm-birth risk assessment (AUC 0.66-0.72 in EveryBaby's comparators).

Others

• Medtronic: Medtronic ANZ is represented on EveryBaby's advisory board and operates broadly across medical devices including women's health and diagnostics — relevant as a potential strategic acquirer and as an adjacent medical-device ecosystem participant.

Emerging players

• Progenity: Emerging prenatal diagnostics company with a comparable pre-commercial/early-commercial trajectory in maternal-fetal testing, useful as a comparable for capital needs and adoption timelines.
• Natera: Prenatal diagnostics company whose Panorama NIPT and Vistara single-gene tests compete for the same hospital prenatal-screening budget; relevant comparable for sales motion and reimbursement dynamics in prenatal care.

Direct peers

• Sera Prognostics: Direct competitor in preterm birth risk prediction — Sera's PreTRM blood-based test is the closest analogous commercial product to EveryBaby's EIS device, addressing the same clinical decision in asymptomatic pregnant women.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/everybaby

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Everybaby Limited